GlassScriptPhysician profile
Andrzej R Maciejewski
NPI 1194780114
$59,908.93
in general payments reported to CMS, 2019-2025
64 companies · $3,188 in 2025
The $3,188 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,340 · 2020: $2,371 · 2021: $2,711 · 2022: $12K · 2023: $23K · 2024: $8,674 · 2025: $3,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $18K · Food and Beverage: $8,981 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Travel and Lodging: $2,833 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $18,450.00 |
| Food and Beverage | $8,980.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Travel and Lodging | $2,833.45 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $29,993.20 | 2021-2023 | Krystexxa, Tepezza |
| Amgen INC. | $8,565.02 | 2019-2025 | Krystexxa, Evenity, Tepezza |
| Janssen Pharmaceuticals, INC | $3,717.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,168.44 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Novartis Pharmaceuticals Corporation | $1,583.26 | 2019-2025 | |
| Lilly USA, LLC | $1,362.67 | 2019-2025 | Taltz, Zepbound, Ebglyss |
| Merck Sharp & Dohme LLC | $892.73 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $823.60 | 2019-2025 | Wegovy, Norditropin |
| Sanofi-Aventis U.S. LLC | $753.18 | 2019-2023 | |
| Medtronic, INC. | $705.47 | 2021-2025 | Minimed 780g, Accurian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.25 | 2019-2025 | Jardiance |
| Allergan, INC. | $487.51 | 2019-2020 | |
| Averitas Pharma INC. | $472.67 | 2023-2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $405.80 | 2019-2025 | Trintellix |
| Abbvie INC. | $381.60 | 2020-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrzej Maciejewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.